




\$ AE/11/10

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. 15838PCT (PC11002B)	
Applicant(s): Willard M. Welch, et al.					
Application No. 10/617,967	Filing Date July 10, 2003	Examiner Emily B. Bernhardt	Customer No. 23389	Group Art Unit 1624	Confirmation No. 4135
Invention: 4-(2-PYRIDYL)PIPERAZINES HAVING 5HT7 RECEPTOR AGONIST ACTIVITY					
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	1 -	20 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____					
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1013/SSMP					
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.					
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
<div style="display:flex; justify-content:space-between;"><div> _____ <i>Signature</i></div><div>Dated: August 4, 2005</div></div>					
<div style="display:flex; justify-content:space-between;"><div>Peter I. Bernstein Registration No. 43,497 Scully, Scott, Murphy & Presser 400 Garden City Plaza, Suite 300 Garden City, New York 11530 516-742-4343</div><div style="border:1px solid black; padding:5px; width:45%;"><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p><p style="text-align:center;">August 4, 2005</p><div style="text-align:center;"> _____ <i>Signature of Person Mailing Correspondence</i></div><p style="text-align:center;">Peter I. Bernstein</p><p style="text-align:center;"><i>Typed or Printed Name of Person Mailing Correspondence</i></p></div></div>					
PIB:dg CC:					



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Willard M. Welch, et al. **Examiner:** Emily B. Bernhardt
Serial No.: 10/617,967 **Art Unit:** 1624
Filed: July 10, 2003 **Docket:** 15838PCT (PC11002B)
For: 4-(2-PYRIDYL)PIPERAZINES **Dated:** August 4, 2005
HAVING 5HT7 RECEPTOR
AGONIST ACTIVITY

Confirmation No.: 4135

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO ADVISORY ACTION

Sir:

In response to the Advisory Action dated May 12, 2005, and further to the Notice of Appeal filed February 28, 2005, the Applicants respectfully submit the following new arguments in the above-identified case:

There are no Amendments to the Specification.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, United States Patent and Trademark Office, P. O. Box 1450, Alexandria, Virginia 22313-1450.

Dated: August 4, 2005


Peter I. Bernstein